In today’s recent session, 1.07 million shares of the 10x Genomics Inc (NASDAQ:TXG) have been traded, and its beta is 1.98. Most recently the company’s share price was $10.88, and it changed around $0.32 or 3.03% from the last close, which brings the market valuation of the company to $1.36B. TXG at last check was trading at a discount to its 52-week high of $24.76, offering almost -127.57% off that amount. The share price’s 52-week low was $6.78, which indicates that the recent value has risen by an impressive 37.68% since then. We note from 10x Genomics Inc’s average daily trading volume that its 10-day average is 4.01 million shares, with the 3-month average coming to 3.75 million.
10x Genomics Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.26. If we narrow it down even further, the data shows that 0 out of 17 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 9 recommended TXG as a Hold, whereas 5 deemed it a Buy, and 1 rated it as Underweight. 10x Genomics Inc is expected to report earnings per share of -0.08 for the current quarter.
10x Genomics Inc (NASDAQ:TXG) trade information
Instantly TXG has been showing a green trend so far today with a performance of 3.03% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 11.18 on recent trading dayincreased the stock’s daily price by 2.68%. The company’s shares are currently down -24.23% year-to-date, but still up 0.93% over the last five days. On the other hand, 10x Genomics Inc (NASDAQ:TXG) is 21.84% up in the 30-day period. We can see from the shorts that 16.02 million shares have been sold at a short interest cover period of 4.44 day(s).
The consensus price target as assigned by Wall Street analysts is $25, which translates to bulls needing to increase their stock price by 56.48% from its current value. Analyst projections state that TXG is forecast to be at a low of $24 and a high of $46.
10x Genomics Inc (TXG) estimates and forecasts
The year-over-year growth rate is expected to be -3.33%, down from the previous year.
Consensus estimates provided by 14 financial analysts predict the company will bring in an average of 139.41M in revenue for the current quarter. 14 analysts expect 10x Genomics Inc to make 143.6M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 153.1M and 151.65M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -8.95%. Forecasts for the next quarter put sales growth at -5.31%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -36.10%. 10x Genomics Inc earnings are expected to increase by 20.48% in 2025, but the outlook is positive 25.49% per year for the next five years.
TXG Dividends
10x Genomics Inc’s next quarterly earnings report is expected to be released on 2025-May-08.
10x Genomics Inc (NASDAQ:TXG)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.93% of 10x Genomics Inc shares, and 102.30% of them are in the hands of institutional investors. The stock currently has a share float of 104.31%. 10x Genomics Inc stock is held by 379.0 institutions, with FMR LLC being the largest institutional investor. By 2024-06-30, it held 10.836% of the shares, which is about 13.01 million shares worth $253.05 million.
VANGUARD GROUP INC, with 8.4863% or 10.19 million shares worth $198.18 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
